Copyright © Inderes 2011 - present. All rights reserved.
  • Uusimmat
  • Pörssi
    • Aamukatsaus
    • Osakevertailu
    • Pörssikalenteri
    • Osinkokalenteri
    • Analyysi
    • Artikkelit
    • Sisäpiirin kaupat
    • Transkriptit
  • inderesTV
  • Mallisalkku
  • Foorumi
  • Premium
  • Femme
  • Nora AI
  • Opi
    • Sijoituskoulu
    • Q&A
    • Analyysikoulu
  • Meistä
    • Seurantayhtiöt
    • Tiimi
Lehdistötiedote

Ortivus is extending its existing credit facility agreement with the company’s main shareholder, Ponderus Invest AB.

Ortivus

The credit facility amounts to 25 MSEK, all of which is currently utilized. The loan amount drawn under the facility carries a fixed annual interest rate of 8%.

Ortivus is in an exciting phase, with several customer projects nearing completion. Among other things, Ortivus is implementing its first installation of MobiMed ePCR (electronic patient care record) in Apple’s iOS ecosystem.

The Group is also close to finalizing processes related to the cyberattack that affected one of its UK-based subcontractors in the summer of 2023. The cyberattack has significantly impacted the Group’s revenues, while also leading to substantial one-off costs. The Group had previously initiated costly processes to obtain compensation for this through insurance and/or damages.

In light of the above, the Board has reached an agreement with the company’s main shareholder, Ponderus Invest, to extend the existing credit facility agreement with Ponderus until 31 December 2025.

Contacts


For further information, please contact

Gustaf Nordenhök, CEO

Telefon +46 8 446 45 00

About Ortivus


Ortivus develops and commercialises MobiMed, e-health and medical technology solutions for a safer and more efficient healthcare. The company was founded in 1985 and is today a leading provider of mobile digital solutions for prehospital care, worldwide. Ortivus' innovations are based on in-depth expertise in cardiology as well as decades of development together with users and customers. The company's headquarters are located in Danderyd, Stockholm. The company has, since 1998, a wholly owned subsidiary based in the United Kingdom and since 2022, a wholly owned subsidiary based in Denmark.

MobiMed is a modular platform that connects and enable real-time information sharing throughout the prehospital care chain. It is currently used by over 12,000 paramedics in over 2,700 emergency vehicles. The platform, MobiMed, consists of several product modules that are completely integrated but can also be used stand-alone. MobiMed comprises four main solutions: MobiMed Monitor, that measures, monitors and shares patients' vital parameters and ECG in real-time, MobiMed ePR, - an electronic patient record for decision support, collection of patient data and clinical documentation, MobiMed enRoute, - a tool for navigation and case management, and MobiMed Life - a range of stand-alone defibrillators.

MobiMed saves vital seconds and enable healthcare professionals make the right decisions in critical situations. MobiMed also contributes to improved quality of care and saved resources.

Ortivus Class A and Class B shares are listed on the NASDAQ Stockholm Small Cap list.
 
Read more about Ortivus at www.ortivus.com

Attachments


Ortivus is extending its existing credit facility agreement with the company’s main shareholder, Ponderus Invest AB.

Sosiaalinen media
  • Inderes Foorumi
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Yhteystiedot
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • Meistä
  • Tiimi
  • Avoimet työpaikat
  • Inderes sijoituskohteena
  • Palvelut pörssiyhtiöille
Sivusto
  • UKK
  • Käyttöehdot
  • Tietosuojaseloste
  • Vastuuvapauslauseke
Inderesin vastuuvapauslauseke löytyy täältä. Kunkin Inderesin aktiivisessa seurannassa olevan osakkeen tarkemmat tiedot löytyvät kunkin osakkeen omilta yhtiösivuilta Inderes-sivustolla. © Inderes Oyj. Kaikki oikeudet pidätetään.